Universität zu Köln

Gisslinger, H., Jeryczynski, G., Gisslinger, B., Wolfler, A., Burgstaller, S., Buxhofer-Ausch, V., Schalling, M., Krauth, M-T, Schiefer, A-I, Kornauth, C., Simonitsch-Klupp, I., Beham-Schmid, C., Mullauer, L. and Thiele, J. (2016). Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria. Leukemia, 30 (5). S. 1126 - 1133. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551

Full text not available from this repository.

Abstract

Essential thrombocythemia (ET) is currently diagnosed either by the British Committee of Standards in Haematology (BCSH) criteria that are predominantly based on exclusion and not necessarily on bone marrow (BM) morphology, or the World Health Organization (WHO) criteria that require BM examination as essential criterion. We studied the morphological and clinical features in patients diagnosed according either to the BCSH (n = 238) or the WHO guidelines (n = 232). The BCSH-defined ET cohort was reevaluated by applying the WHO classification. At presentation, patients of the BCSH group showed significantly higher values of serum lactate dehydrogenase and had palpable splenomegaly more frequently. Following the WHO criteria, the re-evaluation of the BCSH-diagnosed ET cohort displayed a heterogeneous population with 141 (59.2%) ET, 77 (32.4%) prefibrotic primary myelofibrosis (prePMF), 16 (6.7%) polycythemia vera and 4 (1.7%) primary myelofibrosis. Contrasting WHO-confirmed ET, the BCSH cohort revealed a significant worsening of fibrosis-free survival and prognosis. As demonstrated by the clinical data and different outcomes between WHO-diagnosed ET and prePMF, these adverse features were generated by the inadvertent inclusion of prePMF to the BCSH group. Taken together, the diagnosis of ET without a scrutinized examination of BM biopsy specimens will generate a heterogeneous cohort of patients impairing an appropriate clinical management.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Gisslinger, H. UNSPECIFIED UNSPECIFIED UNSPECIFIED Jeryczynski, G. UNSPECIFIED UNSPECIFIED UNSPECIFIED Gisslinger, B. UNSPECIFIED UNSPECIFIED UNSPECIFIED Wolfler, A. UNSPECIFIED UNSPECIFIED UNSPECIFIED Burgstaller, S. UNSPECIFIED UNSPECIFIED UNSPECIFIED Buxhofer-Ausch, V. UNSPECIFIED UNSPECIFIED UNSPECIFIED Schalling, M. UNSPECIFIED UNSPECIFIED UNSPECIFIED Krauth, M-T UNSPECIFIED UNSPECIFIED UNSPECIFIED Schiefer, A-I UNSPECIFIED UNSPECIFIED UNSPECIFIED Kornauth, C. UNSPECIFIED UNSPECIFIED UNSPECIFIED Simonitsch-Klupp, I. UNSPECIFIED UNSPECIFIED UNSPECIFIED Beham-Schmid, C. UNSPECIFIED UNSPECIFIED UNSPECIFIED Mullauer, L. UNSPECIFIED UNSPECIFIED UNSPECIFIED Thiele, J. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-277087
DOI:	10.1038/leu.2015.360
Journal or Publication Title:	Leukemia
Volume:	30
Number:	5
Page Range:	S. 1126 - 1133
Date:	2016
Publisher:	NATURE PUBLISHING GROUP
Place of Publication:	LONDON
ISSN:	1476-5551
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language CHRONIC IDIOPATHIC MYELOFIBROSIS; MASKED POLYCYTHEMIA-VERA; MYELOPROLIFERATIVE NEOPLASMS; DIFFERENTIAL-DIAGNOSIS; HISTOLOGICAL CRITERIA; WORKING GROUP; REPRODUCIBILITY; ANAGRELIDE; MANAGEMENT; GUIDELINE Multiple languages Oncology; Hematology Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/27708